Characterisation of exacerbations of chronic bronchitis and COPD in Europe: The GIANT study

Therapeutic Advances in Respiratory Disease

Volumn 3, Issue 6, 2009, Pages 267-277

  Miravitlles, Marc ^a   Anzueto, Antonio ^b   Ewig, Santiago ^c   Legnani, Delfino ^d   Stauch, Kathrin ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Thoraxzentrum Ruhrgebiet   (Germany)

^d UNIVERSITY OF MILAN   (Italy)

^e BAYER PHARMA AG   (Germany)

Author keywords

chronic bronchitis; chronic obstructive pulmonary disease; exacerbations; moxifloxacin; quality of life

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; MOXIFLOXACIN; QUINOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; EUROPE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; QUESTIONNAIRE; SMOKING; SPIROMETRY;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; BRONCHITIS, CHRONIC; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; QUINOLINES; SMOKING; SPIROMETRY;

EID: 77449133105     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465809352791     Document Type: Article

References (39)

1. Adams, S.G., Anzueto, A., Pugh, J.A., Lee, S. and Hazuda, H.P. (2006) Mexican American elders have similar severities of COPD despite less tobacco exposure than European American elders. Respir Med 100: 1966-1972.
2. Anthonisen, N.R., Manfreda, J., Warren, C.P., Hershfield, E.S., Harding, G.K. and Nelson, N.A. (1987) Antibiotic therapy in exacerbations of chronic pulmonary disease. Ann Intern Med 106: 196-204.
3. Anzueto, A. (2006) Impact of exacerbations in patients with COPD. Hot Topics Respir Dis 2: 7-13.
4. Black, N. (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312: 1215-1218.
5. Buist, A.S., McBurnie, M.A., Vollmer, W.M., Gillespie, S., Burney, P., Mannino, D.M. et al. (2007) for the BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370: 741-750.
6. Chapman, K.R., Mannino, D.M., Soriano, J.B. et al. (2006) Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 27: 188-207.
7. Derom, E., van Weel, C., Liistro, G., Buffels, J., Schermer, T., Lammers, E. et al. (2008) Primary care spirometry. Eur Respir J 31: 197-203.
8. Donaldson, G.C., Seemungal, T.A., Bhowmik, A. and Wedzicha, J.A. (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57: 847-852.
9. Garcia-Aymerich, J., Lange, P., Benet, M., Schnohr, P. and Antó, J.M. (2006) Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 61: 772-778.
10. Halpin, D.M. and Miravitlles, M. (2006) Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc 3: 619-623.
11. Hannan, E.L. (2008) Randomized clinical trials and observational studies. Guidelines for assessing respective strengths and limitations. J Am Coll Cardiovasc Interv 1: 211-217.
12. Kessler, R., Stahl, E., Vogelmeier, C., Haughney, J., Trudeau, E., Löfdahl, C.G. et al. (2006) Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. CHEST 130: 133-142.
13. Koch, H., Landen, H. and Stauch, K. (2004) Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. Clin Drug Investig 24: 449-455.
14. Landen, H., Möller, M., Tillotson, G.S., Kubin, R. and Höffken, G. (2001) Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 29: 51-60.
15. Llor, C., Molina, J., Naberan, K., Cots, J.M., Ros, F. and Miravitlles, M. EVOCA study group. (2008) Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract 62: 585-592.
16. Miravitlles, M. (2007a) Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2: 191-204.
17. Miravitlles, M. (2007b) Do we need new antibiotics for treating exacerbations of COPD? Ther Adv Respir Dis 1: 61-76.
18. Miravitlles, M. and Llor, C. (2007) Determining factors in the prescription of, moxifloxacin, in exacerbations of chronic bronchitis in the primary care setting. Clin Drug Investig 27: 95-104.
19. Miravitlles, M., Anzueto, A., Legnani, D., Forstmeier, L. and Fargel, M. (2007) Patient's perception of exacerbations of COPD - the PERCEIVE study. Respir Med 101: 453-460.
20. Miravitlles, M., de la Roza, C., Naberan, K., Lamban, M., Gobartt, E. and Martin, A. (2007d) Use of spirometry and patterns of prescribing in COPD in primary care. Respir Med 101: 1753-1760.
21. Miravitlles, M., Ferrer, M., Pont, A., Zalacain, R., Alvarez-Sala, J.L., Masa, F. et al. (2004) Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59: 387-395.
22. Miravitlles, M., Guerrero, T., Mayordomo, C., Sánchez-Agudo, L., Nicolau, F. and Segú, J.L. (2000) Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 67: 495-501.
23. Miravitlles, M., Llor, C., Naberan, K., Cots, J.M. and Molina, J., for the EFEMAP study group. (2005) Variables associated with recovery from acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Respir Med 99: 955-965.
24. Miravitlles, M., Molina, J. and Brosa, M. (2007c) Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. Arch Bronconeumol 43: 22-28.
25. Miravitlles, M., Monsó, E., Mensa, J., Aquarón Pérez, J., Barberán, J. and Bárcena Caamaño, M. (2008a) Antimicrobial treatment of exacerbation in chronic obstructive pulmonary disease: 2007 consensus statement. Arch Bronconeumol 44: 100-108.
26. Miravitlles, M., Murio, C., Tirado-Conde, G., Levy, G., Muellerova, H., Soriano, J.B. et al. (2008b) Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruct Pulmon Dis 3: 803-814.
27. Miravitlles, M., Zalacain, R., Murio, C., Ferrer, M., Alvarez-Sala, J.L., Masa, J.F. et al., on behalf of the IMPAC Study Group. (2003) Speed of recovery from acute exacerbations of chronic obstructive pulmonary disease after treatment with antimicrobials: results of a two-year study. Clin Drug Investig 23: 439-450.
28. Niederman, M.S., Anzueto, A., Sethi, S., Choudhri, S., Kureishi, A., Haverstock, D. et al. (2006) Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 100: 1781-1790.
29. Niewoehner, D.E., Collins, D. and Erbland, M.L. (2000) Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 161: 1201-1205.
30. Pitta, F., Troosters, T., Spruit, M.A., Probst, V.S., Decramer, M. and Gosselink, R. (2005) Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171: 972-977.
31. Rabe, K.F., Hurd, S., Anzueto, A., Barnes, P.J., Buist, S.A., Calverley, P. et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
32. Seemungal, T.A.R., Donaldson, G.C., Paul, E.A., Bestall, J.C., Jeffries, D.J. and Wedzicha, J.A. (1998) Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157: 1418-1422.
33. Sobradillo Peña, V., Miravitlles, M., Gabriel, R., Jiménez-Ruiz, C.A., Villasante, C., Masa, J.F. et al. (2000) Geographical variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. CHEST 118: 981-989.
34. Soler-Cataluña, J.J., Martínez-García, M.A., Román Sánchez, P., Salcedo, E., Navarro, M. and Ochando, R. (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60: 925-931.
35. Soriano, J.B. (2007) Epidemiology of chronic obstructive pulmonary disease worldwide. Hot Topics Respir Dis 3: 13-18.
36. Wilson, R., Allegra, L., Huchon, G., Izquierdo, J.L., Jones, P., Schaberg, T. et al. (2004) for the MOSAIC Study Group. (2004) Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. CHEST 125: 953-964.
37. Wilson, R., Jones, P., Schaberg, T., Arvis, P., Duprat-Lomon, I. and Sagnier, P.P. (2006) Antibiotic treatment and factors influencing short and long-term outcomes of acute exacerbations of chronic bronchitis. Thorax 61: 337-342.
38. Woodhead, M., Blasi, F., Ewig, S., Huchon, G., Ieven, M., Ortqvist, A. et al. for the European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases. (2005) Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26: 1138-1180.
39. Yu, C.Y. (2009) Observational studies: a review of study designs, challenges and strategies to reduce confounding. Int J Clin Pract 63: 691-697.